Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy of Metoclopramide in Poor Ovarian Response IVF Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03560583
Recruitment Status : Not yet recruiting
First Posted : June 18, 2018
Last Update Posted : July 4, 2019
Sponsor:
Information provided by (Responsible Party):
Leon Grin, Barzilai Medical Center

Brief Summary:

Poor ovarian response population of ART are considered the biggest challenge for providers. Hitherto, no one protocol has been proven to be effect in this subgroup of IVF patients.

Metoclopramide belongs to the antiemetic group, used for motion sickness and during early gestation for hyperemesis gravidarum.

The mechanism of action is antagonisim to dopamine receptors. We hypothesize than by blocking dopamine receptors and decreasing the dopaminergic tone there is a possibility to increase the sensitivity of ovarian response to gonadotropins during controlled ovarian stimulation and result in increased oocyte retrival.


Condition or disease Intervention/treatment Phase
Poor Responders in IVF Drug: Metoclopramide Drug: Placebo Oral Tablet Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Efficacy of Metoclopramide in Poor Ovarian Response IVF Patients: a Randomised, Double-blind, Placebo-controlled Trial
Estimated Study Start Date : July 2019
Estimated Primary Completion Date : July 2022
Estimated Study Completion Date : July 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Metoclopramide 10 mg BID Drug: Metoclopramide
Metoclopramide 10 mg BID

Placebo Comparator: Placebo 10 mg BID Drug: Placebo Oral Tablet
Placebo 10 mg BID




Primary Outcome Measures :
  1. Number of oocytes [ Time Frame: Approximately 5 weeks from first dose of study drug ]
    Number of oocytes



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 54 Years   (Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Gender Eligibility Description:   Females
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Poor response according to "Bologna criteria"

Exclusion Criteria:

  • Allergy to metoclopramide
  • Prolactinemia
  • Women treated with dopamine agonists

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03560583


Contacts
Layout table for location contacts
Contact: Leon Grin, MD 972-50-5999379 leonti.grin@gmail.com

Sponsors and Collaborators
Barzilai Medical Center
Investigators
Layout table for investigator information
Principal Investigator: Leon Grin, MD Barzilai Medical Center

Publications:
Layout table for additonal information
Responsible Party: Leon Grin, Gynecological Doctor, Barzilai Medical Center
ClinicalTrials.gov Identifier: NCT03560583     History of Changes
Other Study ID Numbers: BRZ 0046-17 CTIL
First Posted: June 18, 2018    Key Record Dates
Last Update Posted: July 4, 2019
Last Verified: July 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Metoclopramide
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Dopamine D2 Receptor Antagonists
Dopamine Antagonists
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action